Safety and efficacy of rituximab versus dimethyl fumarate in patients with relapsing-remitting multiple sclerosis or clinically isolated syndrome in Sweden: a rater-blinded, phase 3, randomised controlled trial

作者：Anders Svenningsson, Thomas Frisell, Joachim Burman, Jonatan Salzer, Katharina Fink, Susanna Hallberg, Joakim Hambraeus, Markus Axelsson, Faiez Al Nimer, Peter Sundström, Martin Gunnarsson, Rune Johansson, Johan Mellergård, Igal Rosenstein, Ahmad Ayad, Irina Sjöblom, Anette Risedal, Pierre de Flon, Eric Gilland, J̇onas Lindeberg, Fadi Shawket, Fredrik Piehl, Jan Lycke · 发表于：The Lancet Neurology · 年份：2022 · DOI：10.1016/s1474-4422(22)00209-5 · 被引用次数：140 · 研究领域：Multiple Sclerosis Research Studies、Polyomavirus and related diseases、Peripheral Neuropathies and Disorders